Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Redhill Biopharma Ltd RDHL

Healthcare
RedHill Biopharma Ltd is an Israel-based specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs such as, Talicia for the treatment of Helicobacter pylori (H. pylori) infection, and Aemcolo, for the treatment of travelers’ diarrhea. RedHill’s clinical late-stage development programs include: :info: RHB-204... see more

Recent & Breaking News (NDAQ:RDHL)

Colliers International reports strong financial results for second quarter

GlobeNewswire July 26, 2016

RedHill Biopharma Receives Additional U.S. Patent Covering RHB-105 Ahead of Confirmatory Phase III Study for H. pylori Infection

GlobeNewswire July 21, 2016

RedHill Biopharma to Host Second Quarter 2016 Financial Results Conference Call on July 26, 2016

GlobeNewswire July 19, 2016

RedHill Biopharma Announces Research Collaboration with NIH for Potential Ebola Treatment

GlobeNewswire July 13, 2016

RedHill Biopharma and IntelGenx Announce Definitive Agreement for Commercialization of RIZAPORT™ for Migraines with Grupo JUSTE in Spain and Additional Potential Territories

GlobeNewswire July 5, 2016

RedHill Biopharma Announces Publication Demonstrating Potential Efficacy of RHB-104 for Crohn's Disease Associated with MAP Infection

GlobeNewswire June 22, 2016

RedHill Biopharma Announces Positive Final Results with Primary and Secondary Endpoints Met in Phase 1 Study with YELIVA™ in Advanced Solid Tumors

GlobeNewswire June 21, 2016

RedHill Biopharma Announces First Patients Dosed in Phase II Study with BEKINDA™ for IBS-D

GlobeNewswire June 20, 2016

RedHill Biopharma to Present at JMP Securities Life Sciences Conference

GlobeNewswire June 15, 2016

RedHill Biopharma to Present at the 2016 BIO International Convention

GlobeNewswire May 31, 2016

RedHill Biopharma to Present at Jefferies 2016 Healthcare Conference

GlobeNewswire May 30, 2016

RedHill Biopharma to Present at BioNetwork East 2016 Partnering Summit

GlobeNewswire April 25, 2016

RedHill Biopharma Reports 2016 First Quarter Financial Results

GlobeNewswire April 20, 2016

RedHill Biopharma to Participate in the FBR & Co. Healthcare Series Focused on Infectious Diseases

GlobeNewswire April 19, 2016

RedHill Biopharma Announces Positive FDA Meeting on RHB-105 Path to Approval and Planned Confirmatory Phase III Study for H. pylori Infection

Thomson Reuters ONE April 18, 2016

RedHill Biopharma to Host First Quarter 2016 Financial Results Conference Call on April 20, 2016

GlobeNewswire April 13, 2016

RedHill Biopharma Initiates Phase II Study of BEKINDA(TM) for Irritable Bowel Syndrome

Thomson Reuters ONE April 11, 2016

RedHill Biopharma Announces Interim Results from Phase IIa Proof-of-Concept Study Supporting Therapeutic Potential of RHB-104 in Multiple Sclerosis

GlobeNewswire March 31, 2016

RedHill Biopharma and IntelGenx Announce RIZAPORT(TM) Commercialization Term Sheet with Grupo JUSTE for Spain and Additional Potential Territories

GlobeNewswire March 29, 2016

RedHill Biopharma to Present at Bio-Europe Spring 2016 Conference

GlobeNewswire March 28, 2016